While the field of gene therapy continues to see success in the form of commercial approvals, the yields needed to meet the demands of these approvals has lagged. Newer, scalable production systems are needed to ensure that the production of products such as AAV can keep up with the clinical and commercial demand.
The TESSA platform provides a promising alternative to traditional AAV production, typically accomplished through triple transfection, which has the potential to alleviate the production bottleneck for AAV vector. Through the introduction of an easy-to-use viral-based transduction system, this platform enables significantly improved AAV yields while overcoming some of the traditional obstacles associated with triple transfection.
This webinar will provide an introduction to the TESSA system, followed by a walkthrough of a client’s approach to initial tests of the novel production system and the subsequent development of the platform.